The use of the common insecticide Ivermectin is associated with lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement and has been recommended by health experts to both prevent and treat Covid-19.
Previously, Ivermectin had shown promise with Covid-19 in vitro. In this study (1) the researchers followed 280 Covid-19 patients in four Broward Health Hospitals in Florida during the period of March 15 th to May 11 th 2020. Some were treated with Ivermectin, others not. Although dosing guidelines were provided, ultimately the Doctor in charge made the final decision. The researchers reviewed all mortality data, with a secondary group of severe pulmonary involvement.
Of the 280 patients, 173 were treated with Ivermectin, and 107 not. Most patients across both groups received either or both Hydroxychloroquine and azithromycin.
Mortality was 24.7% in the non-Ivermectin group but only 13.3% in the Ivermectin-treated patients. This was particularly marked in patients with severe pulmonary involvement with mortality down to 38.8% from 80.7% in non-treated. No significant differences were found in length of stay.
Ivermectin is produced normally by the bacterium Streptomyces avermitilis and kills lice, worms, nematodes and mites by disrupting the fluid exchange through the insect’s cell membrane. The FDA approved the anti-helminthic drug in 2015, stating that it was ‘astonishingly safe’. In other studies it has been shown to extend the effectiveness of chemotherapy drugs (2).
However, the FDA have warned against the use of Ivermectin in Covid cases, saying there is a need for more clinical trials to see if there are any other benefits to patients (?).
In India, a matched case-controlled study amongst health care workers in contact with Covid-19 patients between September and October 2020 showed a 73% reduction in infection in those taking two doses of Ivermectin. Protection lasted approximately one month (3).
In March 2021, a British panel of health experts – The Evidence Based Medical Consultancy – convened a meeting of Health experts from 16 countries, in Bath, who produced a meta-analysis of 20 research studies on Ivermectin. They called for the immediate use of Ivermectin in both treatment of, and prevention of Covid-19 (4).
- Use of Ivermectin is associated with lower mortality in Hospitalized Covid-19 patients; Juliana Cepelowicz Rajter et al; Chest 2021; Jan 159 (1)DOI: 10.1016/j.chest.2020.10.009
2. Ivermectin stops cancer drug resistance
- India health workers Ivermectin study: https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1.full.pdf
- BIRD meeting of Worldwide Health Experts on Ivermectin https://covid19criticalcare.com/wp-content/uploads/2021/03/FLCCC-Release-on-BIRD-meeting-2021-03-09.pdf